688578:SSEShanghai Allist Pharmaceuticals Co. Ltd. Class A Analysis
Data as of 2026-05-28 - not real-time
CN¥88.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The 20‑day SMA sits below the 50‑day SMA, which in turn trails the 200‑day SMA, confirming a clear bearish price trajectory.
The MACD line remains in bearish territory, the signal line is also bearish, and the histogram stays negative, reinforcing downside momentum.
Momentum indicators such as a sub‑50 RSI and a 30‑day volatility exceeding 30% signal heightened short‑term risk, while the price is trading close to its calculated support level and well beneath the identified resistance.
Fundamentally, the company trades at a PE far below the industry average, enjoys robust profit margins, and delivers a sustainable dividend, suggesting a solid value foundation despite the technical weakness.
The MACD line remains in bearish territory, the signal line is also bearish, and the histogram stays negative, reinforcing downside momentum.
Momentum indicators such as a sub‑50 RSI and a 30‑day volatility exceeding 30% signal heightened short‑term risk, while the price is trading close to its calculated support level and well beneath the identified resistance.
Fundamentally, the company trades at a PE far below the industry average, enjoys robust profit margins, and delivers a sustainable dividend, suggesting a solid value foundation despite the technical weakness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price hovering near technical support
- bearish MACD and RSI readings
- elevated 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- significant revenue growth and strong margins
- PE well below industry norm
- sustainable dividend payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- durable business model in a high‑growth biotech niche
- consistent cash generation and low debt‑to‑equity
- long‑run value upside relative to peer PE multiples
Key Metrics & Analysis
Financial Health
Revenue Growth44.20%
Profit Margin42.57%
P/E Ratio16.4
ROE36.09%
ROA21.68%
Debt/Equity0.06
P/B Ratio5.1
Op. Cash FlowCN¥2.5B
Free Cash FlowCN¥1.4B
Industry P/E27.8
Technical Analysis
TrendBearish
RSI36.9
SupportCN¥87.69
ResistanceCN¥97.27
MA 20CN¥92.76
MA 50CN¥94.45
MA 200CN¥99.75
MACDBearish
VolumeStable
Fear & Greed Index93.41
Valuation
Fair ValueCN¥122.48
GradeUndervalued
TypeBlend
Dividend Yield1.11%
Risk Assessment
Beta0.01
Volatility30.32%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.